Publicacións en colaboración con investigadores/as de Universidad de Córdoba (10)

2024

  1. Use of multi-gene panels in patients at high risk of hereditary digestive cancer: position statement of AEG, SEOM, AEGH and IMPaCT-GENÓMICA consortium

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 3, pp. 293-318

2023

  1. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

    Biomedicine and Pharmacotherapy, Vol. 159

2022

  1. Current Positioning against Severe Infections Due to Klebsiella pneumoniae in Hospitalized Adults

    Antibiotics, Vol. 11, Núm. 9

  2. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

    British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880

2021

  1. Controversies in the treatment of RAS wild-type metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 827-839

2018

  1. How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)

    Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111

  2. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

    Oncologist, Vol. 23, Núm. 11, pp. 1271-e128

2015

  1. SECOT-GEIOS guidelines in osteoporosis and fragility fracture. An update

    Revista Espanola de Cirugia Ortopedica y Traumatologia

2011

  1. Somatotroph tumor progression during pegvisomant therapy: A clinical and molecular study

    Journal of Clinical Endocrinology and Metabolism, Vol. 96, Núm. 2

2004

  1. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA)

    European Journal of Endocrinology, Vol. 151, Núm. 4, pp. 439-446